Marsoni S - Search Results

1

Bleomycin, vincristine, and methotrexate (BOM) in squamous cell carcinoma of the lung: a phase II study.

Libretti A, Piazza E, Scanni A, Tomirotti M, Biraghi M, Scapaticci R, Bianchi C, Restelli G, Scarpazza G, Calzavara MP, Marsoni S, Morasca L. Libretti A, et al. Among authors: marsoni s. Cancer Treat Rep. 1981 Jan-Feb;65(1-2):171-2. Cancer Treat Rep. 1981. PMID: 6164485 No abstract available.

2

Phase II study of cyclophosphamide and hexamethylmelamine in non-oat cell bronchogenic carcinoma.

Pisoni MB, Libretti A, Piazza E, Vago G, Scapaticci R, Bianchi C, Tomirotti M, Scanni A, Calzavara MP, Cassani L, Scarpazza G, Marsoni S, Morasca L. Pisoni MB, et al. Among authors: marsoni s. Cancer Treat Rep. 1981 Jul-Aug;65(7-8):731-2. Cancer Treat Rep. 1981. PMID: 6788372 No abstract available.

3

Early phase pharmacokinetics of doxorubicin (adriamycin) in plasma of cancer patients during single- or multiple-drug therapy.

Piazza E, Donelli MG, Broggini M, Sessa C, Natale N, Ottolenghi L, Marsoni S, Libretti A, Mangioni C, Morasca L. Piazza E, et al. Among authors: marsoni s. Cancer Treat Rep. 1980 Aug-Sep;64(8-9):845-54. Cancer Treat Rep. 1980. PMID: 7448822

4

Vincristine and bleomycin do not interfere with infusional plasma levels of methotrexate.

Ottolenghi I, Piazza E, Marsoni S, Trabattoni A, Natale N, Recchia M, Morasca L. Ottolenghi I, et al. Among authors: marsoni s. Eur J Cancer (1965). 1981 Mar;17(3):365-6. doi: 10.1016/0014-2964(81)90129-8. Eur J Cancer (1965). 1981. PMID: 6167447 Clinical Trial. No abstract available.

5

VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma.

Morasca L, Marsoni S, Pisoni MB, Piazza E, Vago G, Casali W, Cogo R, Bianchi C, Scapaticci R. Morasca L, et al. Among authors: marsoni s. Cancer Chemother Pharmacol. 1982;7(2-3):209-10. doi: 10.1007/BF00254551. Cancer Chemother Pharmacol. 1982. PMID: 7083461

6

Plasma levels of cyclophosphamide in patients under polychemotherapeutic regimens.

Ottolenghi L, Morasca L, Marsoni S, Piazza E, Soresi E, Libretti A, Garattini S. Ottolenghi L, et al. Among authors: marsoni s. Biomedicine. 1980 Oct;32(3):123-7. Biomedicine. 1980. PMID: 7448321

7

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.

Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, Bianchi F, Bettini A, Longo F, Moscetti L, Tomirotti M, Marabese M, Ganzinelli M, Lauricella C, Labianca R, Floriani I, Giaccone G, Torri V, Scanni A, Marsoni S; TAILOR trialists. Garassino MC, et al. Among authors: marsoni s. Lancet Oncol. 2013 Sep;14(10):981-8. doi: 10.1016/S1470-2045(13)70310-3. Epub 2013 Jul 22. Lancet Oncol. 2013. PMID: 23883922 Clinical Trial.

8

The phase II trial.

Wittes RE, Marsoni S, Simon R, Leyland-Jones B. Wittes RE, et al. Among authors: marsoni s. Cancer Treat Rep. 1985 Nov;69(11):1235-9. Cancer Treat Rep. 1985. PMID: 4092188 No abstract available.

9

Clinical drug development: an analysis of phase II trials, 1970-1985.

Marsoni S, Hoth D, Simon R, Leyland-Jones B, De Rosa M, Wittes RE. Marsoni S, et al. Cancer Treat Rep. 1987 Jan;71(1):71-80. Cancer Treat Rep. 1987. PMID: 3791270

10

Role of cetuximab in the treatment of patients with NSCLC: are we throwing out the baby with the bath water?

Floriani I, Garassino MC, Broggini M, Veronese S, Marsoni S, Marabese M, Farina G, Scanni A. Floriani I, et al. Among authors: marsoni s. J Clin Oncol. 2010 Sep 20;28(27):e467; author reply e468. doi: 10.1200/JCO.2010.28.5973. Epub 2010 Jun 28. J Clin Oncol. 2010. PMID: 20585086 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

146 results

Search Page

Filters